Hyaluronic acid and its use in non-hormonal therapy for the treatment of vaginal atrophy and the level of awareness about the disease itself among the women from the Podkarpackie Voivodeship
DOI:
https://doi.org/10.12775/QS.2023.14.01.010Keywords
hyaluronic acid, vaginal dryness, vaginal atrophy, dyspareuniaAbstract
Introduction: Hyaluronic acid is the ingredient contained in the composition that has the ability to bind water, found in the cornea, synovial fluid and cartilage stroma. Its properties are suitable for use in an increasing range of fields, both aesthetic and in treatments focusing on the treatment of vaginal atrophy.
Aim of the study: The aim of the study was to collect and analyze publications on the use of hyaluronic acid in the treatment of vaginal atrophy and assessment of the level of knowledge among women about this disease.
Materials and methods: The research material was collected using an anonymous online survey. The obtained results were analyzed and verified on the basis of scientific literaturę and statistically processed using Microsoft Office Excel.
Results: 59,7% of the respondents knew the term "vaginal atrophy" and 64,2% were able to correctly determine which of the hormones (estrogen) is the main cause of this condition. 59,7% of women indicated that they regularly undergo examinations and perform cytology every year, 29,9% indicated that they have examinations and visits "once in 2 years", 6% - "once in 3 years", the answers "less than once in 3 years” was given by 4,5% of the respondents. 85,7% of the surveyed women have never noticed any symptoms of vaginal atrophy and 85,9% believe that there are effective forms of treating this disorder.
Conclusions: Awareness among women about vaginal atrophy, both those with medical education and women in other professions, is at a moderate level. Many women do not talk to their doctor about this not because of the feeling of shame, but also because of the lack of information and preventive measures. The progressive nature of vaginal atrophy should encourage clinicians to routinely engage in an open dialogue with patients about genitourinary health.
References
Domoney C. Treatment of vaginal atrophy. Womens Health (Lond). 2014 Mar;10(2):191-200. doi: 10.2217/whe.14.9. PMID: 24601810.
Berreni N, Salerno J, Chevalier T et al. Evaluation of the effect of multipoint intra-mucosal vaginal injection of a specific cross-linked hyaluronic acid for vulvovaginal atrophy: a prospective bi-centric pilot study. BMC Womens Health. 2021 Aug 28;21(1):322. doi: 10.1186/s12905-021-01435-w. PMID: 34454465; PMCID: PMC8403403.
Nappi RE, Kokot-Kierepa M. Vaginal health: insights, views and attitudes (VIVA) – results from an international survey. Climacteric 15(1), 36–44 (2012).
Andre P. Hyaluronic acid and its use as a "rejuvenation" agent in cosmetic dermatology. Semin Cutan Med Surg. 2004 Dec;23(4):218-22. doi: 10.1016/j.sder.2004.09.002. PMID: 15745228.
Fakhari A, Berkland C. Applications and emerging trends of hyaluronic acid in tissue engineering, as a dermal filler and in osteoarthritis treatment. Acta Biomater. 2013 Jul;9(7):7081-92. doi: 10.1016/j.actbio.2013.03.005. Epub 2013 Mar 15. PMID: 23507088; PMCID: PMC3669638.
Wiest L, Kerscher M. Native hyaluronic acid in dermatology--results of an expert meeting. J Dtsch Dermatol Ges. 2008 Mar;6(3):176-80. English, German. doi: 10.1111/j.1610-0387.2008.06639.x. PMID: 18315621.
Graziottin A, Leiblum SR. Biological and psychosocial pathophysiology of female sexual dysfunction during the menopausal transition. J Sex Med. 2005 Sep;2 Suppl 3:133-45. doi: 10.1111/j.1743-6109.2005.00129.x. PMID: 16422790.
Scavello I, Maseroli E, Di Stasi V, et al. Sexual Health in Menopause. Medicina (Kaunas). 2019 Sep 2;55(9):559. doi: 10.3390/medicina55090559. PMID: 31480774; PMCID: PMC6780739.
Donders GGG, Ruban K, Bellen G, et al. Pharmacotherapy for the treatment of vaginal atrophy. Expert Opin Pharmacother. 2019 May;20(7):821-835. doi: 10.1080/14656566.2019.1574752. Epub 2019 Mar 21. PMID: 30897020.
Caruso S, Rapisarda AM, Cianci S. Sexuality in menopausal women. Curr Opin Psychiatry. 2016 Nov;29(6):323-30. doi: 10.1097/YCO.0000000000000280. PMID: 27584710.
Chen J, Geng L, Song X, et al. Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: a multicenter, randomized, controlled, open-label, parallel-group, clinical trial. J Sex Med. 2013 Jun;10(6):1575-84. doi: 10.1111/jsm.12125. Epub 2013 Apr 9. PMID: 23574713.
Stute P. Is vaginal hyaluronic acid as effective as vaginal estriol for vaginal dryness relief? Arch Gynecol Obstet. 2013 Dec;288(6):1199-201. doi: 10.1007/s00404-013-3068-5. PMID: 24178484.
Scavello I, Maseroli E, Di Stasi V, et al. Sexual Health in Menopause. Medicina (Kaunas). 2019 Sep 2;55(9):559. doi: 10.3390/medicina55090559. PMID: 31480774; PMCID: PMC6780739.
Kogan G, Soltés L, Stern R, et al. Hyaluronic acid: a natural biopolymer with a broad range of biomedical and industrial applications. Biotechnol Lett. 2007 Jan;29(1):17-25. doi: 10.1007/s10529-006-9219-z. Epub 2006 Nov 8. PMID: 17091377.
Berg A, Heidrich F, Fihn S, {et al.]. Establishing the cause of genitourinary symptoms in
women in a family practice. Comparison of clinical examination and comprehensive
microbiology.
JAMA, 1984, 251, 620-625
Sturdee DW, Panay N, on behalf of the International Menopause
Society Writing Group. Recommendations for the management of
postmenopausal vaginal atrophy. Climacteric 2010;13:509–22
The North American Menopause Society. The role of local vaginal
estrogen for treatment of vaginal atrophy in postmenopausal
women: 2007 position statement of The North American
Menopause Society. Menopause 2007;14:357–69
Panay N, Maamari R. Leczenie zaniku po menopauzie za pomocą 10-g estradiolili pochwy. Menopauza Int. 2012 Mar;18(1):15-9. doi: 10.1258/mi.2012.011120. PMID: 22393176.
Schwenkhagen A. Hormonal changes in menopause and impli-
cations on sexual health. J Sex Med 2007;4(Suppl. 3):220–6
Pinkerton JV, Santen RJ. Vaginal atrophy. J Clin Endocrinol Metab. 2011 Nov;96(11):A27, A28. English, Spanish. doi: 10.1210/jcem.96.11.zega27. PMID: 22058386.
Bachmann GA, Nevadunsky NS (2000) Diagnosis and treatment of
atrophic vaginitis. Am Fam Physician 61(10):3090–3096
Alvisi S, Gava G, Orsili I, et al. Vaginal Health in Menopausal Women. Medicina (Kaunas). 2019 Sep 20;55(10):615. doi: 10.3390/medicina55100615. PMID: 31547180; PMCID: PMC6843679.
Archer DF (2010) Efficacy and tolerability of local estrogen therapy
for urogenital atrophy. Menopause 17(1):194–203
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Agata Glac, Kinga Musz, Katarzyna Dobko, Gabriela Frącz, Klaudia Kuliga, Natalia Sejnowska, Agnieszka Socha, Agata Surowiec, Kinga Śnieżek, Anna Zając
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 312
Number of citations: 0